RE:noshNick80 wrote: Hi what are you guys think about:
https://www.avicennatherapeutics.com/technology
Would they be serious competition for ate 346, 352 or 340?
From my understanding their platform might outperform ATE's 340 drug if successful, however what about 346 and others?
Their nosh platform is in pre-clinical only meaning ate is very well advanced and derisked compared to them...
At first glance Nick ... I personally won't be losing sleep over it.
Not only is Wallace on their advisory board, he's also discussing the potential of NOSH-NSAIDs openly in his papers. For him to be on their board, he sees no conflict and he obviously hasn't raised a conflict of interest.
Also, this company seems to be focusing on cancer alone (as per their website information).
-----
Keep in mind too that ATE is in a drug discovery period and with their academic partner and their skillset, we could be well past NOSH designs. If ATE is looking at nano-partilces, bottlebrush, etc... in some tunable form ... we may be in great shape.
There's lots the company needs to share - I'm sure.
I am looking into Avicenna ... just haven't learned much else yet. Anyone ?